Karyopharm Therapeutics, Inc.
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company dedicated to pioneering novel cancer therapies, driven by a belief in the extraordinary strength and courage of patients with cancer. The company focuses on developing medicines targeting patients with cancer in both hematologic malignancies and solid tumors, leveraging core technology in inhibition of nuclear export. With a mission to positively impact patient lives and defeat cancer, Karyopharm supports a culture of innovation, courage, alignment, resilience, and energy. It has a pipeline of FDA-approved drugs and clinical development programs, with a focus on therapies like XPOVIO and Selinexor, among others.
Industries
Nr. of Employees
large (251-1000)
Karyopharm Therapeutics, Inc.
Newton, Massachusetts, United States, North America
Products
XPO1 inhibitor (commercial oncology medicine)
An oral, small-molecule XPO1 (nuclear export) inhibitor that is commercially available for certain oncology indications and is used as monotherapy and in combination regimens in clinical practice and trials.
Eltanexor (clinical-stage oral nuclear export inhibitor)
Oral nuclear export inhibitor in clinical development as monotherapy for hematologic neoplasms (e.g., myelodysplastic neoplasms).
KPT-9274 (dual PAK4/NAMPT inhibitor in development)
Oral small-molecule candidate described as a dual inhibitor of PAK4 and NAMPT in the company's development pipeline.
Verdinexor (clinical-stage nuclear export inhibitor)
Another oral nuclear export inhibitor listed in the clinical pipeline for further development across potential indications.
XPO1 inhibitor (commercial oncology medicine)
An oral, small-molecule XPO1 (nuclear export) inhibitor that is commercially available for certain oncology indications and is used as monotherapy and in combination regimens in clinical practice and trials.
Eltanexor (clinical-stage oral nuclear export inhibitor)
Oral nuclear export inhibitor in clinical development as monotherapy for hematologic neoplasms (e.g., myelodysplastic neoplasms).
KPT-9274 (dual PAK4/NAMPT inhibitor in development)
Oral small-molecule candidate described as a dual inhibitor of PAK4 and NAMPT in the company's development pipeline.
Verdinexor (clinical-stage nuclear export inhibitor)
Another oral nuclear export inhibitor listed in the clinical pipeline for further development across potential indications.
Services
Medical information and adverse event reporting
Telephone and email-based medical information service for healthcare providers and patients, including adverse event and product complaint intake.
Patient support program for therapy access
Online patient support program that provides resources and assistance to patients prescribed company therapies.
Webinar series (educational outreach)
Recurring virtual webinar program providing educational content to medical, scientific, and patient communities, including live Q&A with experts.
Medical affairs / MSL engagement and HCP meeting requests
Coordination of Medical Science Liaison interactions and meeting requests for healthcare professionals via an online callback/meeting request form.
Medical information and adverse event reporting
Telephone and email-based medical information service for healthcare providers and patients, including adverse event and product complaint intake.
Patient support program for therapy access
Online patient support program that provides resources and assistance to patients prescribed company therapies.
Webinar series (educational outreach)
Recurring virtual webinar program providing educational content to medical, scientific, and patient communities, including live Q&A with experts.
Medical affairs / MSL engagement and HCP meeting requests
Coordination of Medical Science Liaison interactions and meeting requests for healthcare professionals via an online callback/meeting request form.
Expertise Areas
- Oncology drug discovery and preclinical development
- Clinical trial management (Phase I–III)
- Nuclear export inhibition therapeutics
- Combination therapy development
Key Technologies
- Nuclear export (XPO1) inhibition
- Oral small-molecule therapeutics
- Combination therapy regimens
- Biomarker/protein activity signature development